PARP1 and neoplasm: PARP inhibitors (PARPi) exert their anti-tumor function by competitively displacing NAD + to bind to the catalytic site of PARP1 and PARP2, thus preventing DNA repair and thereby driving tumor cell death (Rose et al., 2020).